Dr. Kaplan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2650 Ridge Ave
# Kellogg
Evanston, IL 60201Phone+1 847-570-2183Fax+1 847-570-2336
Education & Training
Northwestern University The Feinberg School of MedicinePost-Doctoral Fellowship, 2014 - 2015
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2009- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2003 - 2006
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Internship, Internal Medicine, 2003 - 2004
LSU School of Medicine - New OrleansMD, Medicine, 1999 - 2003
Louisiana State University School of Medicine in New OrleansClass of 2003- University of Texas at AustinBA, Biology, 1993 - 1997
Certifications & Licensure
IL State Medical License 2014 - 2026
TX State Medical License 2009 - 2014
NY State Medical License 2006 - 2009- American Board of Internal Medicine Medical Oncology
- American Board of Internal MedicineInternal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013
Publications & Presentations
PubMed
- 30 citationsTargeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemiaBenedito A. Carneiro, Jason B. Kaplan, Jessica K. Altman, Francis J. Giles, Leonidas C. Platanias
Cancer Biology & Therapy. 2015-03-24 - 15 citationsPhase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell LymphomaLeo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, Silvia Ferrari
Clinical Cancer Research. 2020-07-15 - 5 citationsA phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.Keith W Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W Burke
Haematologica. 2023-03-01
Journal Articles
- Hemophagocytic Lymphohistiocytosis in Cutaneous T-cell LymphomaJaehyuk Choi, Linda M Serrano, Jason B Kaplan, Barbara Pro, Joan Guitart, JAMA
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
